Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 163253-35-8
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15 days
Payment Terms: T/T, L/C, D/A, Western Union
Supply Ability: TON
CAS NO:: |
163253-35-8 |
Appearance :: |
Off-white To Light Yellow Powder |
Molecular Formula:: |
C19H20ClF2N3O4 |
Molecular Weight:: |
427.83 |
EINECS NO:: |
N/A |
MDL NO:: |
MFCD11046360 |
CAS NO:: |
163253-35-8 |
Appearance :: |
Off-white To Light Yellow Powder |
Molecular Formula:: |
C19H20ClF2N3O4 |
Molecular Weight:: |
427.83 |
EINECS NO:: |
N/A |
MDL NO:: |
MFCD11046360 |
Product Description:
Product Name: Sitafloxacin Hydrate CAS NO:163253-35-8
Synonyms:
7-[(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hydrate (2:3);
Chemical & Physical Properties:
Appearance : off-white to light yellow powder
Assay :≥99.0%
Boiling Point:629.2℃ at 760mmHg
Flash Point:334.3℃
Sitafloxacin is a quinolone broad-spectrum antibacterial drug, which was successfully developed by Japan Daiichi Pharmaceutical Sankyo Co., Ltd. It has good pharmacokinetic properties due to its molecular structure containing a cis-fluorocyclopropylamine group. It can reduce adverse reactions, and its in vitro antibacterial activity is significantly enhanced compared with most similar drugs. Oral tablets and fine granules were first launched in Japan in June 2008 for the treatment of severe and refractory infectious diseases. The injection form is undergoing phase III clinical trials in Japan by Japan Daiichi Pharmaceutical Company for the treatment of bacterial infections.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.
